Tirzepatide, a dual GLP-1 and GIP receptor agonist, has demonstrated significant weight reduction across clinical populations, but patients with thyroid conditions need specific safety considerations
Clinical comparisons show tirzepatide can produce: larger HbA1c reductions greater weight loss broader metabolic improvements
Oxidative Stress in Ozone-Induced Chronic Lung Inflammation and Emphysema: A Facet of Chronic Obstructive Pulmonary Disease
Neubert J, Wagner S, Kiwit J, Brauer AU, Glumm J
Now, for what many of you might be wondering about: *maintaining weight loss after GLP-1*
The most relevant recent announcement is Hims & Hers' February 5 launch of a low cost Compounded Semaglutide Pill, which was halted days later under FDA pressure